Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Delivery
Novo, Dicerna to develop liver disease drugs
by Lisa M. Jarvis
November 23, 2019
| A version of this story appeared in
Volume 97, Issue 46
Novo Nordisk will pay Dicerna Pharmaceuticals $225 million, which includes up-front fees and an equity investment, as part of a broad collaboration to develop RNAi-based therapies targeting liver-related diseases. Dicerna’s technology platform hinges on using a substrate for an enzyme called Dicer to deliver a drug into cells, where it can turn off a specific gene. The companies will work on more than 30 liver cell targets, including ones implicated in nonalcoholic steatohepatitis, type 2 diabetes, and obesity.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter